- Home
- BNKK vs QNRX Comparison
BNKK vs QNRX Comparison
Compare BNKK & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNKK | QNRX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BNKK | QNRX |
|---|---|---|
| Price | $2.52 | $6.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.0K | 23.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $5.20 |
| 52 Week High | $7.19 | $41.80 |
Technical Indicators
Market Signals| Indicator | BNKK | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 47.25 |
| Support Level | $2.31 | $5.34 |
| Resistance Level | $2.88 | $6.98 |
| Average True Range (ATR) | 0.21 | 0.46 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 8.53 | 69.13 |
Price Performance
Historical ComparisonAbout BNKK Bonk Inc.
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.